Filgotinib + Anti-Tumor Necrosis Factor Alpha Drug (Product)
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
May 12, 2021 → Sep 30, 2025
NCT ID
NCT04985435About Filgotinib + Anti-Tumor Necrosis Factor Alpha Drug (Product)
Filgotinib + Anti-Tumor Necrosis Factor Alpha Drug (Product) is a approved stage product being developed by Galapagos for Rheumatoid Arthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04985435. Target conditions include Rheumatoid Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Rheumatoid Arthritis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04985435 | Approved | Recruiting |
Competing Products
20 competing products in Rheumatoid Arthritis